Circulating small extracellular vesicles activate TYRO3 to drive cancer metastasis and chemoresistance

• Published in: Cancer research (Chicago, Ill.) Vol. 81; no. 13; pp. 3539 - 3553
• Main Authors: Park, Miso, Kim, Ji Won, Kim, Kyu Min, Kang, Seungmin, Kim, Wankyu, Kim, Jin-Ki, Cho, Youngnam, Lee, Hyungjae, Baek, Moon Chang, Bae, Ju-Hyun, Lee, Seung Hyun, Jeong, Sung Baek, Lim, Sung Chul, Jun, Dae Won, Cho, Sung Yun, Kim, Yeonji, Choi, Yong June, Kang, Keon Wook
• Format: Journal Article
• Language: English
• Published: United States 01.07.2021
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/0008-5472.CAN-20-3320

Extracellular vesicles (EV) in the tumor microenvironment have emerged as crucial mediators that promote proliferation, metastasis, and chemoresistance. However, the role of circulating small EVs (csEV) in cancer progression remains poorly understood. In this study, we report that csEV facilitates cancer progression and determine its molecular mechanism. csEV strongly promoted the migration of cancer cells via interaction with phosphatidylserine of csEV. Among the three TAM receptors TYRO3, AXL, and MerTK, TYRO3 mainly interacted with csEV. csEV-mediated TYRO3 activation promoted migration and metastasis via the epithelial-mesenchymal transition and stimulation of RhoA in invasive cancer cells. Additionally, csEV-TYRO3 interaction induced YAP activation, which led to increased cell proliferation and chemoresistance. Combination treatment with gefitinib and KRCT-6j, a selective TYRO3 inhibitor, significantly reduced tumor volume in xenografts implanted with gefitinib-resistant non-small cell lung cancer cells. The results of this study show that TYRO3 activation by csEV facilitates cancer cell migration and chemoresistance by activation of RhoA or YAP, indicating that the csEV/TYRO3 interaction may serve as a potential therapeutic target for aggressive cancers in the clinic.